Grace Share Price

Grace Share Price

NASDAQ: GRCE | Micro Cap | Healthcare
$1.72
+$0.03 (1.78%) Last updated on 19 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Grace Stock Performance

Open
$1.74
Prev. Close
$1.69
Circuit Range
N/A
Day Range
$1.74 - $1.74
Year Range
$1.65 - $5.15
Volume
129
Average Traded
$1.74

Grace Share Price Today

As of 19 November 2026, Grace Therapeutics, Inc.'s share price is $1.72. The stock opened at $1.74, compared to its previous close of $1.69. During today's trading session, Grace Therapeutics, Inc.'s share price traded between $1.74 and $1.74, with an average price of $1.74. Over the past 52 weeks, the stock has recorded a high of $5.15 and a low of $1.65. In terms of performance, Grace Therapeutics, Inc.'s share price has declined by 33.59% over the last six months and is down 45.91% on a year-on-year basis.

Grace Share Price Chart

Line chart of the Grace price trend over the selected period. The price rose overall, ranging from 1.71 to 1.74, ending at 1.72.
$1.74$1.74
L
Show Current Price
H

Grace Stock Fundamentals & Key Indicators

Market Cap
$20.79M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.02
Revenue (TTM)
$0.00
Return On Equity (TTM)
-38.60%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
8.19%

Grace Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$2.32-$1.18-$15.79-$2.13
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A49.14%-1238.14%86.51%

Grace Annual Profit & Loss

All figures in USD

Particulars20252026
Revenue$0.00$0.00
Net Profit-$9.57-$7.79
Net Profit MarginN/AN/A
Income ChangeN/A18.60%

Grace Balance Sheet

All figures in USD Million

Particulars20262025
Non Current Assets49.2749.28
Current Assets17.3822.71
Total Assets66.6571.99
Non Current Liabilities0.613.45
Current Liabilities2.151.93
Total Liabilities2.765.38
Shareholders' Equity63.966.61

Grace Cash Flow

Annually
Particulars20262025
Operating (USD Million)-8.87-14.9
Investing (USD Billion)0.00.0
Financing (USD Million)3.7114.03

About Grace

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Grace Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.85
$1.74
-8.42%
Oct 2026
$2.11
$1.90
-11.21%
Sep 2026
$2.12
$2.14
-1.15%
Aug 2026
$2.13
$2.17
+3.59%
Jul 2026
$2.32
$2.09
-7.93%
Jun 2026
$2.60
$2.27
-12.36%
May 2026
$2.30
$2.59
+14.60%
Apr 2026
$4.78
$2.26
-51.29%
Mar 2026
$4.19
$4.64
+7.91%
Feb 2026
$3.69
$4.30
+17.49%
Jan 2026
$3.51
$3.66
+4.57%
Dec 2025
$3.19
$3.50
+10.06%

Grace Share Price FAQs